Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Headhunter calls outgoing Leo Pharma CEO a "flop"

It was a mistake to hire Catherine Mazzacco as CEO of Leo Pharma, says a headhunter focused on the pharmaceutical industry, who predicts that the board will look internationally to find her replacement.

Column: The EU pharma strategy must become more ambitious

The general managers at Roche and Novo Nordisk in Denmark are calling for the EU pharma strategy to become more ambitious and visionary, and it should be enhanced in three areas in particular, write Roche’s Darine Ghanem and Novo Nordisk’s Kasper Bødker Mejlvang.

Ambu board member sells 5,000 shares

The employee representative on the board of medtech company Ambu, Jakob Bønnelykke Kristensen, has sold 5,000 shares in the company for just under DKK 1m (USD 150,000).

Latest news

See all jobs